Metastatic Cancers: History and Discovery

Metastasis — the spread of cancer from its original, or primary, site to distant organs — is what makes most cancers lethal. For the great majority of patients who die of cancer, it is not the original tumor but its distant colonies that take their lives. The word metastasis was introduced into cancer medicine by the French surgeon Joseph Claude Anthelme Récamier in 1829, in his treatise on breast cancer. The single most influential idea about how it happens is Stephen Paget's "seed and soil" hypothesis of 1889: studying breast-cancer autopsies, Paget argued that metastases settle not at random but wherever a wandering cancer "seed" meets a hospitable "soil." James Ewing later countered with a mechanical, blood-flow explanation (1928); modern science now recognizes that both are partly right. This page traces the long road from a single coined word to today's detailed map of the metastatic cascade, the tumor microenvironment, the re-validated seed-and-soil concept, and epithelial–mesenchymal transition.

Table of Contents

  1. Why Metastasis Is the Central Problem
  2. Ancient Observations and the Word "Cancer"
  3. Récamier and the Birth of "Metastasis" (1829)
  4. Paget's Seed and Soil Hypothesis (1889)
  5. Ewing and the Mechanical Challenge (1928)
  6. Fidler and the Experimental Re-Validation
  7. Mapping the Metastatic Cascade
  8. Epithelial–Mesenchymal Transition
  9. The Microenvironment and the Modern Synthesis
  10. Research Papers and References
  11. Connections

Why Metastasis Is the Central Problem

A tumor confined to the organ where it began is, in principle, a curable problem: it can often be cut out, burned out, or otherwise removed. What turns cancer into one of the leading causes of death worldwide is its ability to escape that original site and seed new colonies in distant organs — the liver, the lungs, the bones, the brain. It is widely stated in oncology that the large majority of cancer deaths are caused by metastatic disease rather than by the primary tumor itself. Understanding metastasis is therefore not one cancer problem among many; it is, in a very real sense, the cancer problem.

This explains why the history recounted here matters. Every major advance in cancer survival — early screening, the radical surgeries of the twentieth century, chemotherapy, and today's targeted and immune therapies — can be read as an attempt to either prevent metastasis before it happens or to defeat it once it has. The patient whose breast or colon tumor is found and removed before any cell has wandered off has an excellent chance; the patient in whom microscopic colonies have already taken root faces a far harder fight. The scientific story below is, at bottom, the story of how medicine slowly learned what those wandering cells actually do.

It is worth stating plainly, for anyone reading this while living with cancer, that the word "metastatic" is not the verdict it once was. Many metastatic cancers are now managed for years as chronic conditions, and a growing number can be driven into long, durable remission. The history that follows is not a counsel of despair but the record of how each hard-won insight — from a single coined word in 1829 to the molecular maps of today — has steadily expanded what treatment can do.

Back to Table of Contents

Ancient Observations and the Word "Cancer"

The recognition that tumors could spread is far older than the word for it. Physicians of the ancient world saw swollen, hardened glands accompanying breast tumors, and noted that some growths returned in new places after being removed. The Greek physician Hippocrates (c. 460–370 BCE) is traditionally credited with the terms karkinos and karkinoma — "crab" — reportedly because the swollen veins radiating from some tumors suggested a crab's legs, or because of the way the disease gripped and held the body. The Roman encyclopedist Celsus later rendered this into the Latin cancer, the word we still use. These authors are named here as historical sources rather than as modern citations.

For many centuries, however, there was no clear concept of spread as a distinct biological process. The dominant framework, inherited from Galen, attributed cancer to an excess of "black bile" — a systemic humoral imbalance — which left little room for the idea that a tumor seeds physical offspring in distant organs. Distant tumors that appeared after an original cancer were not necessarily understood as descendants of it; they could be read as the same constitutional poison erupting in a new place. This humoral view persisted, in various forms, into the eighteenth century.

The shift came gradually as anatomists and surgeons accumulated careful autopsy observations and began to think of disease in terms of solid organs and tissues rather than circulating humors. By the late eighteenth and early nineteenth centuries, a growing number of surgeons were prepared to see the secondary growths in the lymph nodes, liver, and lungs of a cancer patient as material colonies of the original tumor — physical seeds carried there from somewhere else. It was into this changing intellectual climate that a precise vocabulary for the phenomenon finally arrived.

Back to Table of Contents

Récamier and the Birth of "Metastasis" (1829)

The French physician and surgeon Joseph Claude Anthelme Récamier (1774–1852) is credited with introducing the term metastasis into cancer medicine in 1829. Récamier was a distinguished figure of the Paris medical world — chief physician at the Hôtel-Dieu and a professor at the Collège de France — and an important early figure in what we would now call surgical oncology and gynecology. He set out his observations in his treatise Recherches sur le traitement du cancer… ("Researches on the Treatment of Cancer"), a work principally concerned with the management of breast cancer.

The word itself was not new to medicine; metastasis, from the Greek for "a change of place" or "removal," had long been used in classical and humoral medicine to describe a disease shifting from one part of the body to another. Récamier's contribution was to apply it specifically and deliberately to the spread of cancer — to the formation of distant secondary tumors derived from a primary growth. In observing a patient in whom breast cancer had seeded distant disease, he gave the process a name that physicians could share, and that name has anchored the field ever since. Historical accounts describe Récamier as among the first to clearly recognize and articulate this process of malignant spread.

Récamier's own mechanistic picture reflected his era: he understood cancer as propagating through the veins, with tumor matter invading the bloodstream and being carried elsewhere. That intuition — that the circulation is a highway for spreading cancer — would echo, in a far more developed form, in James Ewing's mechanical hypothesis a century later. What mattered most, however, was the naming. By giving the phenomenon a stable word in 1829, Récamier turned a vague, ancient sense that "the disease moves" into a defined object of study that the next two centuries of medicine could investigate, measure, and eventually dissect step by step.

Back to Table of Contents

Paget's Seed and Soil Hypothesis (1889)

If Récamier supplied the word, the English surgeon Stephen Paget (1855–1926) supplied the idea that still governs the field. In 1889 Paget published a paper in The Lancet titled The distribution of secondary growths in cancer of the breast. He had done something then unusual: he scrutinized the autopsy records of a large series of women — commonly cited as 735 fatal breast-cancer cases — and tabulated exactly where the metastases had landed. The pattern, he saw, was not random.

Paget was struck by a mismatch between blood supply and metastatic burden. Some organs that received a great deal of blood, such as the spleen, were rarely colonized, while others — the liver, certain bones, and the ovaries — were struck far more often than mere blood flow could explain. If metastasis were simply a matter of where the circulation carried tumor cells, the distribution should have tracked the plumbing. It did not. Paget concluded that the destination organ must contribute something of its own: a receptivity, a fertility, that allowed a wandering cancer cell to take root and grow there and not elsewhere.

He framed this with an agricultural metaphor borrowed from a botanical image: when a plant goes to seed, its seeds are carried in all directions, but they only grow where they fall on congenial soil. The metastasizing cancer cell, Paget proposed, is the "seed," and the receptive distant organ is the "soil." Metastasis, in this view, requires a compatible match between the two — which is precisely why different cancers show characteristic, reproducible patterns of organ-specific spread. It is essential to be clear that this was offered as a hypothesis, an interpretation of autopsy statistics, not a proven mechanism; its experimental confirmation lay nearly a century in the future.

The "seed and soil" hypothesis is one of the most durable ideas in all of oncology. More than 130 years on, it remains the conceptual backbone of how researchers think about organ-specific metastasis, and the phrase is used daily in cancer laboratories around the world. Yet for several decades after Paget proposed it, the idea was eclipsed by a rival and more mechanical explanation.

Back to Table of Contents

Ewing and the Mechanical Challenge (1928)

The American pathologist James Ewing (1866–1943) — one of the founding figures of American cancer pathology, and the man whose name is attached to Ewing sarcoma — offered a sharply different account. In his influential textbook Neoplastic Diseases (the relevant edition dated 1928), Ewing argued that the distribution of metastases could be explained by purely mechanical, anatomical factors: the architecture of the blood and lymphatic vessels.

On Ewing's view, a tumor cell or clump of cells (an embolus) that breaks loose and enters the circulation is simply swept along until it lodges in the first capillary bed too narrow to let it pass. The organ that is "downstream" of a given primary tumor — the first filter its venous drainage reaches — will therefore catch the most cells and bear the heaviest metastatic load. There is no need, in this picture, to invoke any special fertility of the soil; the pattern of spread follows from the plumbing alone. This explains, for instance, why colon cancer (whose venous blood drains to the liver) so often metastasizes to the liver, and why many tumors seed the lungs, the body's great venous filter.

Ewing's mechanical hypothesis was powerful, intuitive, and supported by a great deal of clinical anatomy, and it held sway over much of twentieth-century thinking for several decades. But it could not account for everything. It struggled to explain why certain cancers preferentially colonize organs that are not simply the next vascular stop — the notorious affinity of some breast and prostate cancers for bone, or of various tumors for the brain or adrenal glands, in patterns out of proportion to blood flow. These were exactly the anomalies Paget had pointed to. The honest modern verdict is that the two men were each partly right: anatomy and blood flow determine where tumor cells arrive, while the receptivity of the soil determines where they successfully grow. Resolving that, however, required experiments neither man could perform.

Back to Table of Contents

Fidler and the Experimental Re-Validation

For most of a century, "seed and soil" versus "mechanical trapping" remained a debate between two interpretations of clinical and autopsy data. What was missing was the ability to track tumor cells through the body and ask, experimentally, what actually happened to them. That ability arrived with the work of Isaiah J. Fidler (1936–2020) and colleagues, beginning around 1970, using mouse models — especially the B16 melanoma — and radioactively labeled cancer cells.

In a landmark approach, Fidler labeled cultured B16 melanoma cells with a radioactive tracer (¹²⁵I-5-iodo-2′-deoxyuridine), injected them into genetically identical mice, and then measured how many cells survived and where they ended up over time. The results were striking: the overwhelming majority of the injected tumor cells — on the order of 99% — died within roughly a day, and only a tiny minority ever succeeded in establishing a colony. Metastasis, this revealed, is not the easy default fate of a circulating tumor cell but a highly inefficient process that very few cells survive — a finding that reframed the whole problem.

Fidler then went further, showing that the cells which do succeed are not a random sample. By repeatedly selecting the cells that colonized a particular organ and re-injecting them, he demonstrated that metastatic ability is a heritable, selectable trait, and that specific cell populations have specific organ preferences. In experiments transplanting particular mouse tissues into host animals and observing which were preferentially colonized by injected tumor cells, Fidler and his collaborators provided direct experimental support for organ-specific homing. Roughly a century after Paget, his "seed and soil" hypothesis had been confirmed at the bench: the soil really does matter, and not every seed can grow in every field.

Fidler's work did not overturn Ewing so much as place both ideas in their proper relationship and open the modern era. It established metastasis as a problem of cell biology — of which cells can survive, travel, and adapt — rather than of anatomy alone, and it set the stage for dissecting the journey into its individual steps.

Back to Table of Contents

Mapping the Metastatic Cascade

The defining achievement of late-twentieth- and twenty-first-century metastasis research has been to break the once-mysterious leap from primary tumor to distant colony into a defined sequence of steps — the metastatic cascade. Each step is a distinct biological hurdle, and a tumor cell must clear every one of them, in order, to produce a clinically meaningful metastasis. This is why the process is so inefficient, as Fidler had shown: failure at any stage ends the journey.

The cascade is conventionally described as a series of stages. First comes local invasion: cancer cells at the edge of the primary tumor break through the basement membrane and push into the surrounding tissue, often degrading the extracellular matrix that normally holds tissues in place. Next is intravasation, the entry of these cells into the lumen of a blood or lymphatic vessel. Once inside, the cells become circulating tumor cells (CTCs), which must survive in the circulation — resisting the shear forces of flowing blood, evading immune attack, and avoiding death from loss of their normal anchorage. Many travel as clusters, sometimes cloaked in platelets that shield them.

A surviving cell must then arrest in a small vessel at a distant site and extravasate — cross the vessel wall into the tissue of the target organ. Finally, and most demandingly, it must achieve colonization: surviving in a foreign microenvironment, often lying dormant for months or years, and ultimately growing into a vascularized macroscopic tumor. Colonization is widely regarded as the rate-limiting, least-understood step, and it is here that Paget's "soil" exerts its decisive influence. The discovery that primary tumors can actively prepare distant tissues in advance — conditioning a receptive pre-metastatic niche before any tumor cell arrives — was a major refinement of this picture, giving Paget's soil a molecular mechanism.

Back to Table of Contents

Epithelial–Mesenchymal Transition

One of the most important cell-biological concepts to enter metastasis research is the epithelial–mesenchymal transition (EMT) — a programmed change in cell state in which orderly, tightly-bound epithelial cells take on the loosely-attached, mobile, invasive character of mesenchymal cells. EMT offers a compelling explanation for the first steps of the cascade: how a stationary cancer cell, normally cemented to its neighbors, acquires the wandering, shape-shifting behavior needed to invade tissue and slip into the bloodstream.

EMT was not discovered in cancer at all, but in the study of embryonic development, where epithelial-to-mesenchymal conversions are a normal and essential part of building the body. The American developmental biologist Elizabeth D. "Betty" Hay (1927–2007) of Harvard Medical School is widely credited as the first to describe the phenomenon and, later, to give it its name. She brought the idea to prominence at a 1968 symposium, describing how epithelial cells transform into mesenchymal cells during early development; she used the term "epithelial–mesenchymal transformation" in the early 1980s and the now-standard "transition" by the mid-1990s.

Over subsequent decades, researchers recognized that cancer cells appear to reactivate this developmental program to enable invasion and dissemination, and that the reverse process — mesenchymal-to-epithelial transition (MET) — may help disseminated cells settle and grow at the distant site. EMT in cancer has become an enormous and, it should be said, still actively debated field; its precise role and its degree of necessity in human metastasis remain the subject of ongoing research, and the picture is more nuanced than a simple on/off switch. What is not in doubt is that the embryological insight pioneered by Hay reshaped how oncology thinks about the very first move of the metastatic cascade.

Back to Table of Contents

The Microenvironment and the Modern Synthesis

The arc of this history bends toward a synthesis that vindicates, rather than discards, the older ideas. Modern metastasis research no longer treats the tumor as a lump of rogue cells acting alone; it treats it as an ecosystem — a tumor microenvironment of cancer cells together with blood vessels, immune cells, fibroblasts, signaling molecules, and remodeled matrix. Metastasis is understood as a continuous conversation between the traveling cancer cell and the tissues it passes through and lands in. This is, in essence, Paget's "seed and soil" rendered in molecular detail.

In this modern synthesis the long-running Récamier–Paget–Ewing thread is resolved. Ewing's mechanics govern delivery: blood and lymphatic anatomy still largely determine which organs a tumor's cells reach first and in what numbers. Paget's biology governs establishment: whether those delivered cells survive, awaken from dormancy, and grow depends on the compatibility of seed and soil — now known to involve specific molecular signals, immune conditions, and even the pre-metastatic niches that primary tumors prepare from a distance. Both mechanisms operate together, and the "debate" of the early twentieth century is better seen as two halves of one answer.

This understanding is not merely historical bookkeeping; it shapes treatment. Drugs that target the steps of the cascade, therapies aimed at the microenvironment and the immune "soil," and liquid biopsies that detect circulating tumor cells and tumor DNA in the blood all descend directly from the conceptual lineage traced on this page. The journey that began when Récamier put a single Greek word to a deadly phenomenon in 1829 continues in every laboratory now trying to interrupt the cascade before it completes — with the steady, practical goal of turning more metastatic cancers into diseases that can be controlled, and ideally cured. For the clinical picture of how metastatic cancers are detected, staged, and treated today, see the main Metastatic Cancers article.

Back to Table of Contents

Research Papers and References

The list below pairs key peer-reviewed historical and review articles on the science of metastasis with curated PubMed topic-search links into the primary literature. Historical primary texts — Récamier's Recherches sur le traitement du cancer (1829), Paget's 1889 Lancet paper, and Ewing's Neoplastic Diseases (1928) — are named in the article as historical sources. Each link opens in a new tab.

  1. Paget S. The distribution of secondary growths in cancer of the breast. The Lancet. 1889;133(3421):571-573. (Reprinted with commentary in Cancer and Metastasis Reviews. 1989;8(2):98-101.) — PubMed: Paget "seed and soil" 1889 reprint
  2. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. The Lancet Oncology. 2008;9(8):808. — doi:10.1016/S1470-2045(08)70201-8
  3. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nature Reviews Cancer. 2003;3(6):453-458. — doi:10.1038/nrc1098
  4. Fidler IJ. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2′-deoxyuridine. Journal of the National Cancer Institute. 1970;45(4):773-782. — PubMed: Fidler 1970 tumor emboli
  5. Talmadge JE, Fidler IJ. AACR centennial series: the biology of cancer metastasis: historical perspective. Cancer Research. 2010;70(14):5649-5669. — doi:10.1158/0008-5472.CAN-10-1040
  6. Ribatti D, Mangialardi G, Vacca A. Stephen Paget and the 'seed and soil' theory of metastatic dissemination. Clinical and Experimental Medicine. 2006;6(4):145-149. — doi:10.1007/s10238-006-0117-4
  7. Langley RR, Fidler IJ. The seed and soil hypothesis revisited — the role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer. 2011;128(11):2527-2535. — doi:10.1002/ijc.26031
  8. Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168(4):670-691. — doi:10.1016/j.cell.2016.11.037
  9. Valastyan S, Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147(2):275-292. — doi:10.1016/j.cell.2011.09.024
  10. Pearlman RL, et al. Epithelial to mesenchymal transition history: from embryonic development to cancers. Biomolecules. 2021;11(6):782. — doi:10.3390/biom11060782
  11. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. Journal of Clinical Investigation. 2009;119(6):1420-1428. — doi:10.1172/JCI39104
  12. Peinado H, et al. Pre-metastatic niches: organ-specific homes for metastases. Nature Reviews Cancer. 2017;17(5):302-317. — doi:10.1038/nrc.2017.6
  13. Récamier and the history of cancer metastasis — PubMed: Récamier history of cancer metastasis
  14. Metastatic cascade — invasion, intravasation, circulating tumor cells, extravasation, colonization — PubMed: the metastatic cascade

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents